BRISBANE, Calif.–(BUSINESS WIRE)–March 22 September 2022–
Mammoth Biosciences, a biotech company harnessing next-generation CRISPR technology to detect and cure diseases, was selected by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11-Year Special Report.
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220922005355/en/
Comprised of a team of scientific founders, seasoned biopharma veterans and talented researchers, Mammoth is developing a robust pipeline of novel CRISPR systems capable of providing lasting cures for genetic diseases and powering next-generation diagnostic tools to enable decentralized disease detection to allow.
“On behalf of the entire Mammoth team, we are honored to be recognized as an Endpoints 11 company,” said Trevor Martin, co-founder and chief executive officer of Mammoth Biosciences. “The award is a testament to the Mammoth team and the progress we’ve made in building the CRISPR platform that leverages the potential of this transformative technology across the healthcare spectrum. We continue to make strides toward realizing our mission of providing patients access to once-in-a-lifetime permanent cures, made possible by the next generation in vivo Therapeutics and the democratization of disease detection with next-generation molecular diagnostics.”
This is the 20th year that John Carroll has selected top private biotechs for special recognition. Each year, the Endpoints News editor, along with the best backers and scientific founders, searches for the best biotechs that are pioneering new technologies and fresh strategies to search for the next generation of therapeutics.
“The Endpoints 11 special report is always one of the highlights of every year,” says Carroll. “And 2022 is a stellar year with a list of biotechs aiming to make notable successes in the drug-hunting space. It’s a high-risk, high-reward industry, and the Endpoints 11 all have big ambitions. We celebrate their pioneering spirit and expertise.”
The 2022 Endpoints 11 will be hosted live at The 105 in Boston today with an open bar and networking starting at 6pm ET. At 7 p.m. ET, Carroll will join Nobel Laureate and biotech legend Phillip Sharp for an exclusive fireside chat.
“Sharp was part of the birth of the biotech industry as it evolved into a global endeavor where investors amassed while start-ups tackle some of the biggest drug discovery challenges,” Carroll said.
Registration is open to all Biopharma professionals at elf22.endpts.com.
About Mammoth Biosciences
Mammoth Biosciences is harnessing the diversity of life to advance the next generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company enables the full potential of its platform to read and write the code of life. Mammoth aims to develop lasting genetic cures by best-in-class in vivo and ex vivo therapies and the democratization of disease detection with on-demand diagnostics. Leveraging its in-house R&D and exclusive licensing of Cas12, Cas13, Cas14 and Casɸ, Mammoth is able to offer enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences was co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna along with Trevor Martin, Janice Chen and Lucas Harrington. The company is backed by leading institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX and 8VC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005355/en/
CONTACT: John Kang
Email: [email protected]
Telephone: 309-310-4537
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENETICS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Mammoth Biosciences
Copyright Business Wire 2022.
PUB: 09/22/2022 07:30 / DISC: 09/22/2022 07:32
http://www.businesswire.com/news/home/20220922005355/en
Copyright Business Wire 2022.
